Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Toronto

$150,000.00

Establishing the oncogenomic landscape of clinically aggressive meningiomas

EF 2017-18

Résumé
Meningiomas are the most common adult primary brain tumors. Although the majority of meningiomas are benign, subsets of these tumors are clinically aggressive and challenging to treat. These clinically aggressive meningiomas (CAMs) behave similar to cancerous brain tumors. The interventions available to treat CAMs are limited, with surgical resection and radiation therapy as the only two viable options. Even with the most aggressive available forms of treatment, patients are not cured of their tumors and the regrowth of tumors results in considerable morbidity, poor quality of life and significant loss of functional years. A better understanding of the genetic changes associated with CAMs would allow for the development of personalized treatments critical for improving the durability of response and quality of life in these patients. We plan to use multiple genetic-based sequencing techniques to establish the genetic landscape of CAMs and to identify key driver genetic mutations in these tumors. We will correlate our genetic findings with key clinical parameters and quality of life data. The key genetic alterations identified will be selected as possible targetable changes that will be examined using animal studies. Our laboratory has used and published this approach previously for a different brain and spinal tumor (schwanommas, published in Nature Genetics), and we are confident that this approach will establish the genetic landscape for CAMs and will identify new mutations for patients with CAMs that may be targeted to personalize and enhance durability of treatment. This work will establish a comprehensive genomic database harmonized with fundamental clinical and quality of life data that will be unparalleled. The most promising genetic alterations can be translated into clinical practice through Phase I/II clinical trials.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
376553
Name
Nassiri Farshad
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Establishing the oncogenomic landscape of clinically aggressive meningiomas
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Brain Tumors; Cns Oncology; Epigenomics; Genomics; Meningiomas; Quality Of Life
Abstract
Meningiomas are the most common adult primary brain tumors. Although the majority of meningiomas are benign, subsets of these tumors are clinically aggressive and challenging to treat. These clinically aggressive meningiomas (CAMs) behave similar to cancerous brain tumors. The interventions available to treat CAMs are limited, with surgical resection and radiation therapy as the only two viable options. Even with the most aggressive available forms of treatment, patients are not cured of their tumors and the regrowth of tumors results in considerable morbidity, poor quality of life and significant loss of functional years. A better understanding of the genetic changes associated with CAMs would allow for the development of personalized treatments critical for improving the durability of response and quality of life in these patients. We plan to use multiple genetic-based sequencing techniques to establish the genetic landscape of CAMs and to identify key driver genetic mutations in these tumors. We will correlate our genetic findings with key clinical parameters and quality of life data. The key genetic alterations identified will be selected as possible targetable changes that will be examined using animal studies. Our laboratory has used and published this approach previously for a different brain and spinal tumor (schwanommas, published in Nature Genetics), and we are confident that this approach will establish the genetic landscape for CAMs and will identify new mutations for patients with CAMs that may be targeted to personalize and enhance durability of treatment. This work will establish a comprehensive genomic database harmonized with fundamental clinical and quality of life data that will be unparalleled. The most promising genetic alterations can be translated into clinical practice through Phase I/II clinical trials.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Nassiri, Farshad
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~